| ￥2600 | |
| Z05474-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 52 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of IL-20RA hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
IL-20RA hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | IL-20RA was highly expressed in the tumor tissue of CRC and related to the advanced stage.IL-20RA was involved in regulating oncogenic and immune pathways and affecting the expression of genes related to cell proliferation and immune evasion in CRC.Super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA. |
| Synonyms | IL-20R-alpha; IL-20RA; CRF2-8; IL-20R1; ZcytoR7; FLJ40993 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
